51179-05-6

Usage

Uses

Used in Pharmaceutical Applications:
2-(4-Benzyloxy-phenyl)-ethylamine is used as a pharmaceutical compound for its potential role in the treatment of various medical conditions. Its interaction with serotonin receptors suggests that it may be beneficial in conditions related to serotonin dysregulation.
Used in Research Applications:
In the research industry, 2-(4-Benzyloxy-phenyl)-ethylamine is utilized as a research chemical to study its interactions with biological systems, particularly focusing on its effects on serotonin receptors. This helps in understanding its potential therapeutic applications and contributes to drug discovery efforts.
Used in Drug Discovery:
2-(4-Benzyloxy-phenyl)-ethylamine is employed as a lead compound in drug discovery processes. Its unique properties and interactions with serotonin receptors make it a valuable candidate for the development of new therapeutic agents targeting a range of medical conditions.

InChI:InChI=1/C15H17NO/c16-11-10-13-6-8-15(9-7-13)17-12-14-4-2-1-3-5-14/h1-9H,10-12,16H2

Upstream product

• 2982-55-0 1-benzyloxy-4-(2-nitroethenyl)benzene 
• 2982-55-0 (E)-1-(benzyloxy)-4-(2-nitrovinyl)benzene 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 836-43-1 4-benzyloxybenzyl alcohol 
• 836-42-0 4-benzyloxybenzyl chloride 
• 838-96-0 2-[4-(benzyloxy)phenyl]acetonitrile 
• 74447-33-9 1-(2'-azidoethyl)-4-(benzyloxy)benzene 
• 100-39-0 benzyl bromide 
• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 182921-01-3 N-(tert-butoxycarbonyl)-2-[4-(benzyloxy)phenyl]ethylamine 
• 123-08-0 4-hydroxy-benzaldehyde 
• 51-67-2 tyrosamine 
• 2982-54-9 2-[4-(benzyloxy)phenyl]ethylamine hydrochloride 
• 86587-62-4 2-(4'-benzyloxy)phenethyl-p-methylbenzenesulfonate 

Downstream Products

• 103268-70-8 4-Benzyloxy-N-<3.4-dibenzyloxy-benzyl>-phenaethylamin 
• 663597-15-7 [2-(4-benzyloxy-phenyl)-ethyl]-(6-nitro-quinazolin-4-yl)-amine 
• 605657-52-1 N-[2-(4-benzyloxy-phenyl)-ethyl]-4-methoxy-benzamide 
• 389602-52-2 N-[2-(4-benzyloxyphenyl)ethyl]-3-(biphenyl-2-carbonylamino)-benzoic acid amide 
• 164179-34-4 2,2,3-Trimethyl-2H-benzo[b]pyran-6-carboxylic Acid 
• 164179-43-5 6-(N-[2-(4-Benzyloxyphenyl)ethyl]carbamoyl)-2,2,3-trimethyl-2H-benzo[b]pyran 
• 164179-64-0 6-(N-[2-(4-Benzyloxyphenyl)ethyl])carbamoyl-2,2-dimethyl-2H-benzo[b]pyran 
• 171807-14-0 N-(N-(N-(N-(1,1-dimethylethoxycarbonyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
• 1033777-14-8 4-adamantan-1-yl-N-[2-(4-benzyloxyphenyl)ethyl]-2-hydroxybutyramide 
• 1033777-42-2 N-(4-(benzyloxy)phenethyl)-3-adamantan-1-yl-2-hydroxypropanamide 
• 1149745-66-3 C₂₃H₂₀ClN₃O 
• 252061-94-2 6-benzyloxy-1,2,3,4-tetrahydro-isoquinoline 
• 1268607-25-5 [2-(4-benzyloxyphenyl)-ethyl]-pteridin-4-yl-amine 
• 1275548-13-4 4,4',4'',4'''-tetrabenzyloxy-cannabisin G 

Relevant academic research and scientific papers

Enantioselective Sequential-Flow Synthesis of Baclofen Precursor via Asymmetric 1,4-Addition and Chemoselective Hydrogenation on Platinum/Carbon/Calcium Phosphate Composites

Continuous-flow synthesis of baclofen precursor (2) was achieved using achiral and chiral heterogeneous catalysts in high yield with high enantioselectivity. The key steps are chiral calcium-catalyzed asymmetric 1,4-addition of a malonate to a nitroalkene and chemoselective reduction of a nitro compound to the corresponding amino compound by using molecular hydrogen. A dimethylpolysilane (DMPS)-modified platinum catalyst supported on activated carbon (AC) and calcium phosphate (CP) has been developed that has remarkable activity for the selective hydrogenation of nitro compounds.

Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors

Concerned by the devastating effects of Alzheimer's disease, and the lack of effective drugs, we have carried out the design of a series of tacrine-phenolic heterodimers in order to tackle the multifactorial nature of the disease. Hybridization of both pharmacophores involved the modification of the nature (imino, amino, ether) and the length of the tether, together with the type (hydroxy, methoxy, benzyloxy), number and position of the substituents on the aromatic residue. Title compounds were found to be strong and selective inhibitors of human BuChE (from low nanomolar to subnanomolar range), an enzyme that becomes crucial in the more advanced stages of the disease. The lead compound, bearing an ether-type tether, had an IC50 value of 0.52 nM against human BuChE, and a selectivity index of 323, with an 85-fold increase of activity compared to parent tacrine; key interactions were analysed using molecular modelling. Moreover, it also inhibited the self-aggregation of Aβ42, lacking neurotoxicity up to 5 μM concentration, and showed neuroprotective activity in primary rat neurons in a serum and K+ deprivation model, widely employed for reproducing neuronal injury and senescence. Moreover, low hepatoxicity effects and complete stability under physiological conditions were found for that compound. So, overall, our lead compound can be considered as a promising multitarget-directed ligand against Alzheimer's disease, and a good candidate for developing new drugs.

SYNTHESIS OF POLYCYCLIC ALKALOIDS

Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused

PTERIDINES AND THEIR USE AS AGROCHEMICALS

The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

PTERIDINES AND THEIR USE AS AGROCHEMICALS

The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

The total synthesis of cannabisin G

A convenient method for the synthesis of lignanamide cannabisin G, starting from vanillin, was developed. The convergent synthesis was based on the Stobbe reaction as C-C bond-forming steps to give the skeleton of lignan, which was condensed with a deriva

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors

Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea.

Structure-based approach to falcipain-2 inhibitors: Synthesis and biological evaluation of 1,6,7-Trisubstituted dihydroisoquinolines and isoquinolines

1,4,7-Trisubstituted isoquinolines were designed, synthesized and evaluated for their inhibition against Plasmodium falciparum cysteine protease falcipain-2. The 1-benzyloxyphenyl-dihydroisoquinoline and -isoquinoline derivatives were found to exhibit better activity against falcipain-2 than their corresponding 1-hydroxyphenyl or 1-methoxyphenyl analogues. The docking scores correlate with the IC50 values of compounds and give a high coefficient correlation of 0.94.

Compounds and pharmaceutical use thereof

PCT No. PCT/JP97/00291 Sec. 371 Date Aug. 6, 1998 Sec. 102(e) Date Aug. 6, 1998 PCT Filed Feb. 6, 1997 PCT Pub. No. WO97/29079 PCT Pub. Date Aug. 14, 1997The compounds of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.